Minimal Residual Disease Testing Progress in Breast Cancer Highlighted at ASCO

In the study presented at the American Society of Clinical Oncology (ASCO), the ICR team found that a positive NeXT Personal test result was associated with high risk of future relapse and shortened overall survival, with a median lead time from ctDNA detection to clinical relapse of 15 months.

Investigators said that MRD was identified in all 11 patients who eventually relapsed. Meanwhile, no patients with a negative test result relapsed during the follow-up period. Discounting serial test results and focusing on a single post-surgery landmark time point, 94 percent of patients who tested negative remained relapse-free.

Source: https://www.genomeweb.com/liquid-biopsy/minimal-residual-disease-testing-progress-breast-cancer-highlighted-asco